Table 3.
Summary of univariate analyses of overall survival
| Parameters | n | Hazard ratio (95% CI) | p value |
|---|---|---|---|
| Age |
|
1.05 (0.98–1.12) |
0.19* |
| Gender |
|
|
|
| Female |
17 |
1 |
0.72 |
| Male |
64 |
1.21 (0.52–3.65) |
|
| PS (ECOG) |
|
|
|
| 0 |
55 |
1 |
0.61 |
| 1–2 |
26 |
1.23 (0.42–3.65) |
|
| T stage |
|
|
|
| T1a |
42 |
1 |
|
| T1b, T2a |
39 |
2.38 (1.05–5.39) |
0.04* |
| CTV |
|
1.01 (1.00–1.03) |
0.05* |
| PTV |
|
1.00 (0.99–1.01) |
0.29 |
| Histology |
|
|
0.78 |
| Adenocarcinoma |
35 |
1 |
|
| Squamous cell carcinoma |
27 |
1.46 (0.47–4.57) |
0.51 |
| Unproven |
17 |
1.18 (0.35–3.92) |
0.79 |
| Tumor location |
|
|
|
| Peripheral |
6 |
1 |
|
| Central |
75 |
1.29 (0.30–5.51) |
0.73 |
| Operability |
|
|
|
| Yes |
21 |
1 |
|
| No |
60 |
1.03 (0.43–2.43) |
0.94 |
| Total dose |
|
|
|
| 48 Gy |
60 |
1 |
|
| 60 Gy | 21 | 0.99 (0.93–1.07) | 0.87 |
Abbreviations: ECOG Eastern Cooperative Oncology Group, CIconfidence interval.
*p < 0.2.